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We read with interest a recent article in Psychotherapy 
and Psychosomatics reporting the consensus of 27 experts 
on what should be communicated to patients about pla- 
cebo and nocebo effects and how clinicians should be 
trained to deliver this information [1]. The authors pro- 
pose that communicating general information to patients 
about placebo and nocebo effects is beneficial but should 
be adjusted to the context. They further propose that 
training clinicians to communicate about placebo and 
nocebo effects should be a regular and integrated part of 
medical education. These recommendations build on an 
earlier consensus statement regarding maximizing pla- 
cebo effects and minimizing nocebo effects in clinical 
practice [2]. In response, we argue that the latest consen- 
sus statement is conceptually ambiguous and does not 
accord with recent research on the views of patients and 
clinicians. Furthermore, the presentation of these con- 
sensus statements belies lively debates and disagreements 
in placebo study research, including on fundamental is- 
sues such as the dominance of cognitivist accounts of pla- 
cebo and nocebo effects [3, 4]. 
As the authors note, their method did not allow them 
to draw conclusions about specific strategies that can 
maximize placebo effects and minimize nocebo effects. 
This is, of course, because “placebo” and “nocebo” are 
merely umbrella terms that, though useful for coordinat- 
ing research, encompass a diverse array of situation-de- 
pendent practices too numerous to mention – practices 
that patients and clinicians engage in and talk about with- 
out the need for abstract umbrella terms. As a previous 
editorial position of Psychotherapy and Psychosomatics 
on the clinical inadequacy of the placebo model suggests 
[5], the attempt to offer general guidelines and training 
on placebo and nocebo effects risks obscuring what can 
be better communicated more precisely [6, 7]. 
Conceptual concerns notwithstanding, recommend- 
ing that tailored, evidence-based explanations of placebo 
and nocebo effects should be explained to patients – and 
that the terms themselves are acceptable – is at odds with 
recent systematic reviews of the use and understanding of 
clinical placebo effects. For example, one qualitative syn- 
thesis of 28 studies in primary care concluded that there 
is so much disconnect between modern scientific defini- 
tions of placebo effects and how patients and clinicians 
understand them, that attempts to bridge this gap are un- 
likely to succeed [8]. This not only undermines potential 
communication and training strategies but also questions 
the existing prevalence of use data and broader empirical 
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findings on placebo effects in clinical practice [8, 9]. 
Moreover, although the recommendation for guidelines 
and training in communicating about placebo and no- 
cebo effects is well intentioned, given the unmanageable 
number of existing guidelines in modern evidence-based 
medicine [10], it is unlikely that clinicians will have time 
to meaningfully engage. What should clinicians tell pa- 
tients about placebo and nocebo effects? In most cases 
probably nothing. In most cases – except certain specific 
scenarios – there are likely less confusing and contentious 
ways in which to talk about phenomena the umbrella 
terms purport to encompass. 
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